Fed’s Powell opens door to potential rate cuts at Jackson Hole
SOUTH SAN FRANCISCO - Senti Biosciences, Inc. (NASDAQ:SNTI), a volatile biotech stock currently trading at $1.69 near its 52-week low, has completed the dose finding phase and confirmed the recommended Phase 2 dose for its SENTI-202 therapy in an ongoing Phase 1 clinical trial for relapsed/refractory acute myeloid leukemia (AML), the company announced Thursday.
The clinical-stage biotechnology company, which develops cell and gene therapies using its Gene Circuit platform, is now enrolling additional patients in the dose expansion phase of the trial.
The U.S. Food and Drug Administration has granted Orphan Drug Designation for SENTI-202 to treat AML, according to the company statement. Senti also received an additional $1 million tranche from the California Institute for Regenerative Medicine’s grant for advancing the clinical development of this therapy.
"We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML at the RP2D," said Timothy Lu, Co-Founder and CEO of Senti Biosciences. The company expects to release additional efficacy and durability data from the ongoing Phase 1 study before the end of 2025.
In its financial results, Senti reported cash and cash equivalents of $21.6 million as of June 30, 2025, compared to $48.3 million at the end of 2024. Research and development expenses were $10 million for the second quarter, up from $9.2 million in the same period last year. General and administrative expenses increased to $6.8 million from $4.2 million year-over-year. According to InvestingPro analysis, while the company maintains a healthy current ratio of 4.22, it’s quickly burning through cash, a common challenge for clinical-stage biotechs.
The company posted a net loss of $14.7 million, or $0.56 per share, for the three months ended June 30, 2025.
Senti also announced recent appointments to strengthen its leadership team, including Bryan Baum to the Board of Directors and Dr. James B. Trager to the Scientific Advisory Board.
In other recent news, Senti Biosciences, Inc. has received Orphan Drug Designation from the U.S. Food and Drug Administration for SENTI-202, an innovative CAR NK cell therapy aimed at treating relapsed or refractory hematologic malignancies, including Acute Myeloid Leukemia (AML). This therapy is currently in Phase 1 clinical trials and is designed to target specific cancer cells while sparing healthy ones. Furthermore, analysts at Laidlaw have initiated coverage on Senti Biosciences with a Buy rating, citing the promising potential of SENTI-202 in treating AML. The company has also appointed Bryan Baum, a co-founder of K5 Global, to its Board of Directors, bringing valuable entrepreneurial experience to the team. Additionally, Senti Biosciences recently presented at the BioScience Forum, where they discussed their logic-gated CAR-NK cell therapy approach to cancer treatment. The company has released an animated video detailing the mechanism of action of SENTI-202, highlighting its selective targeting capabilities. These developments underscore Senti Biosciences’ ongoing efforts to advance its innovative therapies in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.